Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Toolkit Designed to Expand Resources for Genomic Research

By BiotechDaily International staff writers
Posted on 28 Aug 2013
Image: The PhenX toolkit homepage. Use of PhenX toolkit measures helps researchers understand the relationships between genetics, health, disease, and environment (Photo courtesy of PhenX Toolkit, RTI).
Image: The PhenX toolkit homepage. Use of PhenX toolkit measures helps researchers understand the relationships between genetics, health, disease, and environment (Photo courtesy of PhenX Toolkit, RTI).
Use of a new genotype/phenotype resource should help researchers better determine the links between genetics, disease, health, and the environment.

As part of a new award from the US National Human Genome Research Institute (Bethesda, MD, USA), RTI International (Research Triangle Park, NC, USA) will expand the PhenX Toolkit, a web-based resource that supports collaborative genomics and biomedical research.

The goals of the four-year, USD 5.3 million award, the genomic resource grant for PhenX Toolkit include updating and expanding the Toolkit, integrating Chinese and Spanish translations of PhenX protocols and mapping PhenX variables to all completed studies in the database of genotypes and phenotypes (dbGaP).

“This award gives the PhenX team the opportunity to address the evolving needs of the scientific community by enhancing the content and features of the Toolkit,” said Carol M. Hamilton, PhD, director of bioinformatics at RTI and PhenX lead investigator. “The use of PhenX measures increases the opportunities for researchers to combine or compare their findings, thus increasing the impact of each individual study.”

The PhenX Toolkit, a web-based catalog of 339 well-established measures of phenotypes and exposures, combines data from a range of research and allows investigators to enlarge a study design beyond the basic research focus. Enhancements to PhenX measurements will increase the overall impact of individual studies by making it easier to compare and combine data.

“The PhenX Toolkit is a great resource for investigators who would like to strategically expand their study design by adding a few standard measures,” Dr. Hamilton said. “Because common, complex diseases share many risk factors, identification of these factors increases with the use of common measures in research studies.”

PhenX is driven by the scientific community and decisions are reached using an established consensus process. Since 2007, the RTI-led PhenX project has engaged working groups of experts to select high-priority measures and a steering committee to provide guidance and policymaking decisions.

The PhenX Toolkit currently has more than 1,100 registered users and is publically available at no cost online (please see Related Links below).

Related Links:

RTI International
PhenX Toolkit



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.